09 Nov 2026, 16:09 IST
Dr. Reddy's Laboratories Limited
Shriram Financial Services Private Limited (Formerly known as Way2Wealth Brokers Pvt. Ltd.) · Buy
The report notes a 1.5% YoY revenue decline and 24% YoY EBITDA decline in Q2FY27 due to lower lenalidomide sales, but states the company remains confident of medium-term growth from semaglutide relaunch, biosimilars and CDMO expansion, maintaining a Buy rating with FY27/FY28 estimates revised down for FY27 and mixed for FY28.
From RR09112026ba19b, written by Shriram Financial Services Private Limited (Formerly known as Way2Wealth Brokers Pvt. Ltd.) and hosted by Way2Wealth. Orivam summarised it; the view is Shriram Financial Services Private Limited (Formerly known as Way2Wealth Brokers Pvt. Ltd.)'s, not Orivam's.
Open the original PDF on Way2Wealth →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.